Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01856881 · ClinicalTrials.gov registry record · Phase 1
Multiple Ascending Dose Study in Subjects With Type 2 Diabetes
A Phase 1 study, sponsored by Amgen.
- Terminated
- Registry status
- Phase 1
- Development phase
- 86
- Enrollment target
NCT01856881: Clinical Trial Phase 1 study, sponsored by Amgen.
NCT01856881 is a Phase 1 study that was terminated before completion, run by Amgen. The registered enrollment target is 86 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (43% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01856881, a Phase 1 study, was terminated before completion, sponsored by Amgen.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 86 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics following ascending multiple doses of AMG 876 in subjects with type 2 diabetes.
Primary Outcome
Physical examinations, vitals, laboratory analytes, and ECGs
Interventions
- DRUG AMG 876
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2013-03 |
| Est. Completion | 2015-03 |
| Phase | Phase 1 |
Why NCT01856881 stopped before completion
NCT01856881 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 86 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (43% higher).
The record links to 0 conditions, and to 1 intervention - of which AMG 876 is the first listed.
NCT01856881 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01856881 about?
NCT01856881 is a clinical study titled "Multiple Ascending Dose Study in Subjects With Type 2 Diabetes". The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics following ascending multiple doses of AMG 876 in subjects with type 2 diabetes.
What is the current status of trial NCT01856881?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 86 participants. The study started on 2013-03. Estimated completion is 2015-03.
What interventions are being tested in trial NCT01856881?
The interventions under investigation include: AMG 876 (DRUG).
Who is sponsoring clinical trial NCT01856881?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01856881's enrollment target sits among peer trials
86 652nd of 2000 higher than 1,345 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01639508 · 86 participants · Phase 2
Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity
- NCT03519269 · 86 participants · NA
Navio Robotic Versus Conventional Total Knee Arthroplasty
- NCT04132999 · 86 participants · NA
PAP for Children With DS and OSAS
- NCT04545957 · 86 participants · NA
Jump: MR Simulation For Radiation Therapy Master Protocol
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia